A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib

Min Zhang; Huan Zhou; Dan Liu; Ruoying Yu; Jun Chen

doi:10.1016/j.jtocrr.2020.100106

A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib

JTO Clin Res Rep. 2020 Oct 17;2(2):100106. doi: 10.1016/j.jtocrr.2020.100106. eCollection 2021 Feb.

Authors

Min Zhang¹, Huan Zhou¹, Dan Liu¹, Ruoying Yu², Jun Chen¹

Affiliations

¹ Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, People's Republic of China.
² Department of Research and Development, Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Ontario, Canada.

Abstract

Most patients with NSCLC, initially sensitive, will develop resistance after a period of time after the application of ALK inhibitors. We present here a rare LOC285000-ALK-NCK2 gene fusion with response to crizotinib treatment; the patient achieved a progression-free survival of 23 months.

Keywords: ALK gene; Crizotinib; Lung cancer.

Publication types

Case Reports